Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/KANK1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/KANK1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/KANK1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/KANK1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/KANK1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/KANK1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/KANK1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/KANK1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/KANK1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001063118 | Oral cavity | OSCC | epithelial cell migration | 174/7305 | 357/18723 | 1.04e-04 | 7.70e-04 | 174 |
GO:006082810 | Oral cavity | OSCC | regulation of canonical Wnt signaling pathway | 128/7305 | 253/18723 | 1.11e-04 | 8.16e-04 | 128 |
GO:009013218 | Oral cavity | OSCC | epithelium migration | 175/7305 | 360/18723 | 1.18e-04 | 8.54e-04 | 175 |
GO:009013018 | Oral cavity | OSCC | tissue migration | 176/7305 | 365/18723 | 1.92e-04 | 1.29e-03 | 176 |
GO:001097510 | Oral cavity | OSCC | regulation of neuron projection development | 210/7305 | 445/18723 | 2.35e-04 | 1.52e-03 | 210 |
GO:00971788 | Oral cavity | OSCC | ruffle assembly | 29/7305 | 44/18723 | 2.74e-04 | 1.74e-03 | 29 |
GO:006007010 | Oral cavity | OSCC | canonical Wnt signaling pathway | 148/7305 | 303/18723 | 2.89e-04 | 1.82e-03 | 148 |
GO:190303418 | Oral cavity | OSCC | regulation of response to wounding | 87/7305 | 167/18723 | 3.91e-04 | 2.38e-03 | 87 |
GO:190002418 | Oral cavity | OSCC | regulation of substrate adhesion-dependent cell spreading | 35/7305 | 57/18723 | 5.10e-04 | 2.98e-03 | 35 |
GO:003444618 | Oral cavity | OSCC | substrate adhesion-dependent cell spreading | 59/7305 | 108/18723 | 7.01e-04 | 3.89e-03 | 59 |
GO:00071629 | Oral cavity | OSCC | negative regulation of cell adhesion | 145/7305 | 303/18723 | 9.95e-04 | 5.18e-03 | 145 |
GO:00301779 | Oral cavity | OSCC | positive regulation of Wnt signaling pathway | 73/7305 | 140/18723 | 1.06e-03 | 5.46e-03 | 73 |
GO:00350245 | Oral cavity | OSCC | negative regulation of Rho protein signal transduction | 16/7305 | 22/18723 | 1.40e-03 | 6.79e-03 | 16 |
GO:00466263 | Oral cavity | OSCC | regulation of insulin receptor signaling pathway | 38/7305 | 66/18723 | 1.70e-03 | 8.07e-03 | 38 |
GO:19000763 | Oral cavity | OSCC | regulation of cellular response to insulin stimulus | 37/7305 | 64/18723 | 1.76e-03 | 8.31e-03 | 37 |
GO:00726734 | Oral cavity | OSCC | lamellipodium morphogenesis | 13/7305 | 17/18723 | 1.92e-03 | 8.94e-03 | 13 |
GO:006104116 | Oral cavity | OSCC | regulation of wound healing | 69/7305 | 134/18723 | 2.19e-03 | 9.95e-03 | 69 |
GO:190303615 | Oral cavity | OSCC | positive regulation of response to wounding | 40/7305 | 72/18723 | 3.21e-03 | 1.38e-02 | 40 |
GO:001076918 | Oral cavity | OSCC | regulation of cell morphogenesis involved in differentiation | 51/7305 | 96/18723 | 3.43e-03 | 1.45e-02 | 51 |
GO:19000276 | Oral cavity | OSCC | regulation of ruffle assembly | 20/7305 | 31/18723 | 3.57e-03 | 1.49e-02 | 20 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
KANK1 | SNV | Missense_Mutation | rs761714605 | c.2255N>T | p.Ser752Leu | p.S752L | Q14678 | protein_coding | deleterious(0.01) | benign(0.219) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
KANK1 | SNV | Missense_Mutation | rs775231755 | c.3806N>T | p.Thr1269Met | p.T1269M | Q14678 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-AC-A62V-01 | Breast | breast invasive carcinoma | Male | <65 | III/IV | Targeted Molecular therapy | denosumab | PD |
KANK1 | SNV | Missense_Mutation | novel | c.2756N>T | p.Ser919Ile | p.S919I | Q14678 | protein_coding | tolerated(0.2) | benign(0.08) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
KANK1 | SNV | Missense_Mutation | | c.2482N>C | p.Glu828Gln | p.E828Q | Q14678 | protein_coding | tolerated(0.08) | probably_damaging(0.981) | TCGA-AO-A03O-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD |
KANK1 | SNV | Missense_Mutation | novel | c.3775N>A | p.Asp1259Asn | p.D1259N | Q14678 | protein_coding | deleterious(0.04) | possibly_damaging(0.737) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
KANK1 | SNV | Missense_Mutation | novel | c.2071N>T | p.Leu691Phe | p.L691F | Q14678 | protein_coding | tolerated(0.41) | benign(0.003) | TCGA-BH-A0E1-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
KANK1 | SNV | Missense_Mutation | novel | c.847N>G | p.Thr283Ala | p.T283A | Q14678 | protein_coding | tolerated(0.09) | probably_damaging(0.917) | TCGA-BH-A0HA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
KANK1 | SNV | Missense_Mutation | | c.3232N>A | p.Glu1078Lys | p.E1078K | Q14678 | protein_coding | deleterious(0.04) | benign(0.147) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
KANK1 | SNV | Missense_Mutation | novel | c.908C>T | p.Ser303Leu | p.S303L | Q14678 | protein_coding | deleterious(0.03) | benign(0.005) | TCGA-E2-A2P6-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
KANK1 | SNV | Missense_Mutation | novel | c.1960G>A | p.Ala654Thr | p.A654T | Q14678 | protein_coding | tolerated(0.62) | benign(0) | TCGA-OL-A5RW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |